About Bis(monoacylglycero)phosphate synthase CLN5
Bis(monoacylglycero)phosphate synthase CLN5 (CLN5) is a protein
from Homo sapiens identified by UniProt accession
O75503, 358 residues long.
MolForge cross-references it against 0 known binders and
325 disease associations.
Target properties
| Protein name | Bis(monoacylglycero)phosphate synthase CLN5 |
| UniProt accession | O75503 |
| Gene | CLN5 |
| Organism | Homo sapiens |
| Length | 358 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (325)
Diseases linked to this target (Open Targets).
- CLN5 disease · score 0.81
- neuronal ceroid lipofuscinosis 5 · score 0.81
- neuronal ceroid lipofuscinosis · score 0.67
- intellectual disability, short stature, facial anomalies, and joint dislocations · score 0.48
- genetic disorder · score 0.47
- chronotype measurement · score 0.36
- Abnormality of metabolism/homeostasis · score 0.34
- pontocerebellar hypoplasia type 2 · score 0.27
- blood protein measurement · score 0.25
- circadian rhythm · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75503-F1 | alphafold | PREDICTED | 82.29 | — |
Amino-acid sequence (358 residues)
MAQEVDTAQG AEMRRGAGAA RGRASWCWAL ALLWLAVVPG WSRVSGIPSR RHWPVPYKRF DFRPKPDPYC QAKYTFCPTG SPIPVMEGDD DIEVFRLQAP VWEFKYGDLL GHLKIMHDAI GFRSTLTGKN YTMEWYELFQ LGNCTFPHLR PEMDAPFWCN QGAACFFEGI DDVHWKENGT LVQVATISGN MFNQMAKWVK QDNETGIYYE TWNVKASPEK GAETWFDSYD CSKFVLRTFN KLAEFGAEFK NIETNYTRIF LYSGEPTYLG NETSVFGPTG NKTLGLAIKR FYYPFKPHLP TKEFLLSLLQ IFDAVIVHKQ FYLFYNFEYW FLPMKFPFIK ITYEEIPLPI RNKTLSGL
Explore Bis(monoacylglycero)phosphate synthase CLN5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets